| pubmed-article:2134116 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2134116 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2134116 | lifeskim:mentions | umls-concept:C0014544 | lld:lifeskim |
| pubmed-article:2134116 | lifeskim:mentions | umls-concept:C1261322 | lld:lifeskim |
| pubmed-article:2134116 | lifeskim:mentions | umls-concept:C0069772 | lld:lifeskim |
| pubmed-article:2134116 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2134116 | pubmed:dateCreated | 1992-4-13 | lld:pubmed |
| pubmed-article:2134116 | pubmed:abstractText | A double-blind placebo-controlled between-patient study was carried out to assess the effects of oxiracetam (CGP 21690E) on memory function in patients with epilepsy. During a 12-week period, either oxiracetam (800 mg t.i.d.) or placebo was given to 30 patients. Twenty-four of the patients had a partial epilepsy. Most patients were on monotherapy carbamazepine. Effect of oxiracetam on memory and related cognitive functions were assessed, using a computerized neuropsychological testing method, while concomitant electrophysiological changes were investigated with routine EEG registration, power spectrum analysis and auditory evoked event-related potentials (P300). Subjective evaluation of well-being was quantified with a mood rating scale. The results did not show any meaningful changes in memory function. This finding is in line with the subjective patient reports and the P300 measures. | lld:pubmed |
| pubmed-article:2134116 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2134116 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2134116 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2134116 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2134116 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2134116 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2134116 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2134116 | pubmed:issn | 0302-282X | lld:pubmed |
| pubmed-article:2134116 | pubmed:author | pubmed-author:de VriesJJ | lld:pubmed |
| pubmed-article:2134116 | pubmed:author | pubmed-author:MeinardiHH | lld:pubmed |
| pubmed-article:2134116 | pubmed:author | pubmed-author:van Emde... | lld:pubmed |
| pubmed-article:2134116 | pubmed:author | pubmed-author:AldenkampA... | lld:pubmed |
| pubmed-article:2134116 | pubmed:author | pubmed-author:AlphertsW CWC | lld:pubmed |
| pubmed-article:2134116 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:2134116 | pubmed:author | pubmed-author:HaverkortH... | lld:pubmed |
| pubmed-article:2134116 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2134116 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:2134116 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2134116 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2134116 | pubmed:pagination | 90-101 | lld:pubmed |
| pubmed-article:2134116 | pubmed:dateRevised | 2006-7-19 | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:meshHeading | pubmed-meshheading:2134116-... | lld:pubmed |
| pubmed-article:2134116 | pubmed:articleTitle | Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy. | lld:pubmed |
| pubmed-article:2134116 | pubmed:affiliation | Institute voor Epilepsiebestrijding; Meer & Bosch/De Cruquiushoeve, Heemstede, Nederland. | lld:pubmed |
| pubmed-article:2134116 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2134116 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2134116 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
